US20060153811A1 - Use of viruses and virus-resistant microorganisms for controlling microorganism populations - Google Patents

Use of viruses and virus-resistant microorganisms for controlling microorganism populations Download PDF

Info

Publication number
US20060153811A1
US20060153811A1 US11/033,022 US3302205A US2006153811A1 US 20060153811 A1 US20060153811 A1 US 20060153811A1 US 3302205 A US3302205 A US 3302205A US 2006153811 A1 US2006153811 A1 US 2006153811A1
Authority
US
United States
Prior art keywords
virus
microorganism
viruses
mutant
introducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/033,022
Other languages
English (en)
Inventor
Lee Jackson
Rex Spendlove
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OMILYTICS Inc
Omnilytics Inc
Original Assignee
OMILYTICS Inc
Omnilytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OMILYTICS Inc, Omnilytics Inc filed Critical OMILYTICS Inc
Priority to US11/033,022 priority Critical patent/US20060153811A1/en
Assigned to OMILYTICS, INCORPORATED reassignment OMILYTICS, INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JACKSON, LEE E., SPENDLOVE, REX S.
Priority to AU2006203859A priority patent/AU2006203859A1/en
Priority to CA2593680A priority patent/CA2593680C/en
Priority to KR1020077018327A priority patent/KR20070118072A/ko
Priority to CNA2006800044501A priority patent/CN101115393A/zh
Priority to MX2007008391A priority patent/MX349342B/es
Priority to PCT/US2006/000854 priority patent/WO2006074460A2/en
Priority to EP06717987.9A priority patent/EP1845784B1/en
Priority to JP2007550568A priority patent/JP2008526892A/ja
Publication of US20060153811A1 publication Critical patent/US20060153811A1/en
Priority to US11/831,813 priority patent/US20070292395A1/en
Priority to US12/027,209 priority patent/US8821855B2/en
Assigned to OMNILYTICS, INCORPORATED reassignment OMNILYTICS, INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JACKSON, LEE E., SPENDLOVE, REX S.
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40Viruses, e.g. bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20Bacteria; Substances produced thereby or obtained therefrom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23BPRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
    • A23B4/00General methods for preserving meat, sausages, fish or fish products
    • A23B4/14Preserving with chemicals not covered by groups A23B4/02 or A23B4/12
    • A23B4/18Preserving with chemicals not covered by groups A23B4/02 or A23B4/12 in the form of liquids or solids
    • A23B4/20Organic compounds; Microorganisms; Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to viruses which control and prevent growth of harmful microorganisms and to processes which employ such viruses. It also relates to protection of helpful microorganisms from virus attack.
  • the viruses of the present invention lack genes for virulence factors, toxins, antibiotic resistance, and other undesirable genes, and include host-range (h-mutant) viruses which are specific for wild-type virus-resistant strains of targeted microorganisms. More specifically, viruses of the present invention are lytic, thus they control and prevent further growth of harmful microorganisms that infect animals or plants by destroying these microorganisms. Such viruses may also be employed to develop and select strains of beneficial microorganisms which are resistant to wild-type and h-mutant viruses.
  • Viruses are known to alter populations of microorganisms, such as bacteria, fungi, algae, and protozoa. It has been estimated that, in nature, as many as one-third of all bacteria may be attacked by viruses each day. The destruction of microorganisms by viruses results in fluctuations of microbial populations in the environment, which is referred to as “cycling” of microbial populations. For example, populations of microorganisms increase in concentration until viruses contact and infect susceptible microorganisms, which are referred to as host microorganisms or “hosts.” Viral infections of microorganisms decrease the number of available susceptible host microorganisms, and correspondingly increase the number of viruses.
  • Bacterial viruses which are also referred to as “bacteriophages” or “phages,” are ubiquitous and can be isolated from all bacterial populations where hosts can be cultivated and used for isolation. Phages are naturally-occurring entities that are found in or on animals (including humans), plants, soil, and water. Viruses which infect algae, molds, mycoplasmas, protozoa, rickettsiae, yeasts, and other microorganisms are also known.
  • Two methods are typically employed in order to determine the concentration, which is also referred to as “quantification,” of viruses in natural environments.
  • electron microscopy may be used to visualize and count total viral particles in a sample of known size.
  • viable viruses may be cultured, or grown, and counted.
  • An exemplary method of quantification by culturing and counting includes a technique which is typically referred to as a plaque assay.
  • plaque assays the viruses that are to be quantified are mixed with a predetermined concentration of host cells and transferred to a liquid (e.g., buffer, mineral salts diluent, or broth). The mixture is then transferred to a semisolid growth medium.
  • the concentration of host cells must be sufficiently great to form a confluent layer, which is typically referred to as a “lawn,” in the semisolid growth medium as the cells grow.
  • a plaque in the semisolid growth medium as the cells grow.
  • many of the viable viruses infect host cells.
  • new viruses are produced within infected host cells, which are eventually destroyed, or “lysed,” so that new viruses may be released therefrom.
  • the new viruses attack and eventually lyse cells that are adjacent to host cells from which the new viruses were released.
  • This spread of infection which continues as long as host cells are metabolizing, results in formation of clear areas, which are typically referred to as “plaques,” in the host cell lawn.
  • the number of viruses that were present in the original mixture is determined by counting the number of plaques that are formed in the host cell lawn. Accordingly, viruses that are quantified by this method are referred to a plaque-forming units (“PFU”).
  • PFU plaque-forming units
  • Phages are also present in foods. Kennedy et al. (1986) Distribution of coliphages in various foods, J. Food Protect. 49:944, found Escherichia coli and phages that attack E. coli (“coliphages”), in 11 of 12 tested foods, each of which are available in many retail markets. For example, all ten ground beef samples tested by Kennedy et al. were contaminated with coliphages. Coliphages were also present in samples of fresh chicken, fresh pork, fresh oysters, fresh mushrooms, lettuce, chicken pot pie, biscuit dough, deli loaf, deli roasted turkey and packaged roasted chicken. Similarly, Gautier et al.
  • Viruses infect and destroy both beneficial and undesirable microorganisms.
  • Soil microorganisms that enhance plant growth and microorganisms that degrade toxic substances are exemplary of beneficial microorganisms in the environment.
  • Undesirable microorganisms include pathogenic microorganisms and algae that cause algal blooms and fish kills.
  • Staphylococcus aureus Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Salmonella typhi, Hemophilus ducreyi, Hemophilus influenzae, Mycobacterium tuberculosis, Neisseria gonorrhoeae, Pseudomonas aeruginosa , various Shigella species, members of the Enterobacteriaceae and Pseudomonas families, and other bacterial species are resistant to many of the conventionally-employed antibiotics. Infections that are acquired during hospitalization, which are typically referred to as nosocomial infections, cause an estimated 60,000 deaths per year, and require treatment, which has been estimated to cost about $4.5 billion per year recently.
  • microorganisms may transfer genetic information, which is referred to as “genes,” or “DNA” for simplicity.
  • Methods by which microorganisms, such as bacteria, can transfer DNA, and even entire genes, include conjugation, transformation, and transduction.
  • Various genes including genes that impart bacteria with resistance to antibiotic drugs, may be transferred from a first, or donor, microorganism to a second, or recipient, microorganism.
  • microorganisms may transfer genes that enable a microorganism to produce toxins, which are typically harmful to an infected host. Virulence factors, which determine the types of hosts and host cells that a microorganism can infect may also be transferred from one microorganism to another.
  • conjugation plasmid or chromosomal DNA is transferred directly from a donor microorganism to a recipient microorganism by means of specialized pili or “sex pili,” which are small, hollow, filamentous appendages, which bind to and penetrate the cell membrane of recipient microorganisms.
  • Conjugation is a process by which genes that code for antibiotic resistance in the “donor” microorganism pass to a recipient microorganism, transforming the recipient into an antibiotic-resistant microorganism.
  • Transformation is the transfer of DNA that has been released into the environment by a donor microorganism and incorporated by a recipient microorganism. Transformation experiments have been conducted in sterile soil that was inoculated with two parental strains of Bacilus subtilis with differentially marked, or tagged, DNA. Bacteria were isolated which carried the markers of both parental strains. Even under the best laboratory conditions, however, transformation is relatively inefficient and requires high densities of donor DNA and recipient cells. Conditions that would permit transformation in many microorganisms are typically not present in a natural, or uncontrolled, environment. Consequently, transformation is typically perceived as a laboratory phenomenon.
  • Transduction is the transfer of host genes to recipient microorganisms by viruses, such as phages.
  • viruses such as phages.
  • phages There are two kinds of phages, virulent, or lytic, and temperate.
  • new phages which are typically referred to as progeny
  • progeny new phages
  • temperate phages typically infect host cells without destroying their host.
  • temperate phages typically incorporate their genetic information into the DNA of the host cell.
  • Many temperate phage-infected host cells can be subsequently induced, by ultraviolet light, mutagens, or otherwise, to enter a lytic cycle, wherein genetic information of the temperate phage produces progeny which then lyse the host cell.
  • Transduction of host DNA may be either “specialized” or “generalized.”
  • a temperate phage's genome is integrated into the chromosome of a host donor microorganism without lysing the host.
  • the phage genome that was inserted into the host chromosome is referred to as a “provirus,” or “prophage,” and is passively replicated as the host cell and its chromosome replicate.
  • Bacteria that carry proviruses are said to be lysogenic. Certain events, such as exposing the host microorganism and the provirus to ultraviolet light, may cause the provirus to act as a virulent phage, whereby the provirus is excised from the bacterial chromosome.
  • Such excised proviruses may carry bacterial genes, or “donor” genes, with them. Upon infecting a new host, or recipient microorganism, these “donor” genes may be expressed, which may alter the phenotype, or physical gene expression, of the recipient microorganism.
  • Temperate and, possibly, some virulent phages may effect generalized transduction.
  • a section of DNA of the donor microorganism which is referred to as a “donor” gene, rather than the phage genome, may be enclosed inside a phage head.
  • Phages that include only DNA of a host microorganism are referred to as transducing particles.
  • a typical phage is only capable, however, of containing about one percent of the chromosome of a host, or “donor,” microorganism. Thus, the simultaneous transfer of more than one gene by a single transducing particle is unlikely. Since transducing particles do not include a phage genome, transducing particles cannot produce progeny upon infecting a recipient microorganism.
  • the donor gene has to be incorporated into the chromosome of the recipient microorganism. If the recipient microorganism is infected with only one transducing particle, it will survive and its phenotype may be altered by the integrated donor gene. It is very important to remember if the multiplicity of infection (“MOI”) of transducing particles per recipient microorganism is high, the cell will probably be destroyed, which is typically referred to as “lysis from without.”
  • MOI multiplicity of infection
  • the transfer of genetic information from one microorganism to another may have beneficial or undesirable effects.
  • a beneficial transfer of genetic information was disclosed by Chakrabarty, A. M. (1996) Microbial degradation of toxic chemicals: Evolutionary insights and practical considerations, ASM News 62:130.
  • Microorganism-rich soil was introduced into a chemostat which contained a single industrial pollutant as a nutrient.
  • pseudomonads which had acquired all of the enzymes needed to degrade the pollutant were isolated from the soil.
  • genes that exhibit undesirable traits may also be transferred.
  • detrimental gene transfer include transfer of genes carrying resistance to antibiotics, and genes that code for production of toxins, such as shiga, diphtheria, and botulism toxins.
  • Genes that code for cholera toxin are also reported to have been transmitted by a temperate phage, which created yet another epidemic strain, Vibrio cholerae 0139.
  • Viruses have been isolated and employed in treating various types of bacterial infections.
  • the treatment of corn plants with Erh 1 reduced the incidence of ice nucleation damage by about 20% to 25%.
  • Kozloff et al. also discloses that Erh1 killed only about 90% of cultured E. herbicola , which suggests that some of the remaining 10% were resistant to wild-type Erh1.
  • Patent application Ser. No. 08/222,956 (the “'956 application”), which was published on Oct. 12, 1995 as WO 95/27043, discloses a type of phage therapy whereby mutant phage strains are introduced into a bacterially infected host.
  • the mutant phages which are thought to be resistant to degradation by the bacterially infected host's defense systems, particularly organs of the reticulo endothelial system, are believed to attack the harmful bacteria with which the host is infected.
  • phages of the '956 application are believed to act as an in vivo antibacterial agent, and may be used either alone or as an adjunct to antibiotic therapy.
  • phages disclosed in the '956 application are introduced into bacterially infected hosts for the purpose of attacking undesirable bacteria, these phages included not only lytic, but also temperate viruses which are able to transfer pieces of donor bacterial DNA to recipient bacteria. Further, the '956 application lacks any disclosure that phages disclosed therein are able to attack, and thereby prevent or otherwise control the further growth of, phage-resistant bacterial strains.
  • phage therapy Shortly after the discovery of phages as lytic agents of bacteria by Twort in 1915 and by d'Herelle in 1917, the investigation of their use for treating bacterial infections, which is typically referred to as phage therapy, began.
  • Various phages are active against bacteria of many diseases in plants and animals, such as mammals.
  • Phages that are active against bacteria which cause human diseases, such as anthrax, bronchitis, diarrhea, scarlet fever, typhus, cholera, diphtheria, gonorrhea, paratyphus, bubonic plague, osteomyelitis, and other bacterially induced diseases are known.
  • phage therapy was successfully employed to treat nosocomial infections caused by antibiotic-resistant bacteria and certain opportunistic pathogens, namely, pyogenic infections and septicemias, especially staphylococcal, but also pseudomonads, enterobacteria ( E.
  • phages may be administered orally in liquids, tablets and capsules, topically by aerosols and direct application, and intravenously. Phage therapy was conducted alone and in combination with antibiotics. Phages were also used as antiseptics, including uses such as disinfecting operating rooms, surgical instruments and lesions on patients, and medical care professionals.
  • Microorganisms such as bacteria can develop phage-resistant strains, however.
  • phage therapy or virus therapy for non-bacterial microorganisms
  • virus therapy is somewhat undesirable from the standpoint that virus-resistant strains of a target strain of microorganism may persist in an infected host that is being treated, or in any other treated environment.
  • beneficial microorganism populations are threatened by viruses that will interfere with the beneficial properties of such microorganisms.
  • Exemplary beneficial processes that are facilitated by microorganisms include industrial fermentation (e.g., in making food products), bioremediation of toxic chemicals, pollutants, and other undesirable substances, leaching of metals from low grade ores, extraction of petroleum and related products from shale, and drug manufacture.
  • the efficiency of many beneficial processes is degraded by the ubiquitous nature of many viruses that will attack the microorganisms that facilitate these processes.
  • temperate viruses have been used to control populations of microorganisms as previously described, many microorganisms can readily develop resistance to infection by viruses. Moreover, the use of temperate viruses in controlling populations of microorganisms is often ineffective since temperate viruses do not always proliferate in and lyse the infected host microorganisms.
  • Wild-type is defined herein as those viruses isolated from the wild or nature which display the most frequently observed phenotype, or physical characteristic, and is typically referred to as “normal,” in contrast to “mutant.” “Wild-type viruses” exhibit normal host-range virulence. “Wild-type microorganisms” do not resist infection by wild-type viruses specific for the particular target strain of microorganism.
  • H-range mutant viruses which are also referred to as “h-mutant viruses,” are defined herein as viruses which exhibit broader than normal host-range virulence. H-mutant viruses infect both wild-type microorganisms and virus-resistant variants of the target strain of microorganisms.
  • the invention thus includes one or more viruses which do not carry unwanted genes and are specific for one or more target strains of microorganisms.
  • the viruses are lytic viruses which may be employed in processes including the control, reduction, or elimination of populations of a target strain of a microorganism.
  • a virus or virus mixture according to the present invention includes one or more h-mutant viruses.
  • a mixture of one or more h-mutant viruses and one or more wild-type viruses is also within the scope of the present invention. Wild-type and h-mutant viruses “recognize” receptors on the surfaces of target strains, including one or more virus-resistant variant thereof, and infect these virus-resistant variants.
  • viruses of the present invention comprise lytic viruses
  • infected host cells will be lysed by the viruses.
  • Viruses which are able to infect the wild-type of the target strain as well as a variety of virus-resistant variants of the target strain are preferred.
  • the h-mutant viruses of the present invention may be generated by isolating a wild-type of a target strain of a microorganism and growing this wild-type in the presence of a wild-type virus which is specific for the target strain. Virus-resistant variants of the target strain will grow in the presence of the wild-type virus. The virus-resistant variants of the target strain are isolated and then grown in the presence of wild-type virus in order to generate h-mutant viruses. H-mutant virus-resistant variants of the target strain may then be obtained in a similar manner to the generation of virus-resistant variants of the target strain.
  • h-mutant virus-resistant variants may then be grown in the presence of h-mutant viruses in order to generate secondary h-mutants which will infect one or more virus-resistant variants of the target strain, imparting these h-mutants with a broader host range than their predecessors.
  • the invention also includes the virus-resistant and h-mutant virus-resistant variants of the microorganism, which are generated as described previously, and as hereinafter further described.
  • the viruses of the present invention may then be employed in a method of controlling, reducing, or eliminating populations of target strain microorganisms.
  • the method includes introducing lytic viruses that are substantially devoid of undesirable genes into an environment where an undesirable target strain microorganism is present. As the target strain microorganism is exposed to the viruses, it is infected and eventually lysed. Since h-mutant viruses preferably infect wild-type and virus-resistant variants of the target strain, depending upon the concentration of h-mutant viruses, the preferred use of h-mutant viruses in the inventive method may effectively control, reduce, or eliminate the target strain microorganisms from the environment into which viruses are introduced.
  • the method of controlling populations of microorganisms includes introducing virus-resistant or h-mutant virus-resistant variants of a microorganism into an environment where the presence of the microorganism is desired.
  • the introduction of such virus-resistant and h-mutant virus-resistant microorganisms is desirable in situations where the microorganism facilitates a beneficial process.
  • the present invention preferably includes host range-mutant lytic viruses, which are also referred to as h-mutant virulent viruses, or simply as h-mutant viruses, that infect and destroy virus-resistant strains of microorganisms.
  • the present invention may also include wild-type lytic, or virulent, viruses, which are collectively referred to as “viruses” for simplicity.
  • the viruses are preferably substantially free of undesirable genes.
  • the present invention also includes a process for generating h-mutant viruses or mixtures of h-mutant and wild-type viruses that lack undesirable genes, such as genes that impart the virus with the ability to infect multicellular organisms, the ability to transfer undesirable genes to infected host microorganisms, and the ability to convert from a lytic state to a temperate state; a process for reducing, eliminating or otherwise controlling the growth of microorganism populations with h-mutant viruses or mixtures of h-mutant and wild-type viruses; and a process that utilizes h-mutant viruses or mixtures of h-mutant and wild-type viruses to generate virus-resistant and h-mutant virus-resistant strains of microorganisms.
  • the virus-resistant and h-mutant virus-resistant strains of microorganisms that are generated by the inventive process are also within the scope of the present invention.
  • the h-mutant viruses of the present invention are lytic, or virulent, viruses, which infect host microorganisms, utilize the various components of the host microorganisms to replicate and assemble progeny, and destroy the host, target strain microorganisms.
  • the h-mutant viruses of the present invention lack undesirable characteristics, including, without limitation, the ability to infect multicellular organisms, the ability to transfer undesirable genes to infected host microorganisms, and the ability to convert from a lytic state to a temperate state.
  • the viruses include an outer protein coat, or “capsid,” which is capable of “recognizing” a receptor, or receptor site, on the outer surface of a target strain microorganism, including some receptors which have been altered, or “mutated,” to impart the target strain microorganism with resistance to wild-type viruses or resistance to one or more h-mutant viruses.
  • the ability of h-mutant viruses to recognize mutated receptors of the target strain microorganism enables h-mutant viruses to infect virus-resistant variations of the target strain microorganism.
  • viruses of the present invention specifically infect the target strain, and do not infect other, non-targeted strains of a same species of microorganism, other non-targeted microorganisms, or other non-targeted cells.
  • the inventive viruses are not as likely to inhibit the activity of beneficial microorganisms as antimicrobial drugs, which lack the specificity of viruses for a target microorganism.
  • the inventive viruses proliferate as they destroy target strain microorganisms, reducing the need for repeated dosing in treatment which include the administration of viruses.
  • antimicrobial therapies require repeated doses since antimicrobial concentrations decrease during treatment.
  • the viruses After target strain microorganism populations are reduced or eliminated such that target strains are no longer present for the viruses to infect, the viruses become inactive, and will eventually be degraded. Following their degradation, the various components of the viruses may be utilized by other organisms as nutrients.
  • the process of generating h-mutant viruses of the present invention includes isolating virus-resistant microorganisms, and growing the virus-resistant microorganisms in the presence of wild-type viruses in order to generate and isolate h-mutant viruses.
  • a target strain of a microorganism is isolated by techniques which are known in the art.
  • the target strain may then be identified or otherwise analyzed by known processes.
  • Virus-resistant members of the target strain are then isolated by culturing the target strain in a medium that facilitates growth, or proliferation, of the target strain.
  • target strain microorganisms are grown on a sterilized, semi-solid medium, such as an agar.
  • the target strain is grown in the presence of a wild-type virus that is capable of infecting the former.
  • the concentration of the wild type virus depends upon the desired MOI.
  • the relative concentrations of target strain microorganisms to wild-type viruses are about one-to-one, for an MOI of about one.
  • wild-type virus-resistant microorganisms Due to their ability to resist infection by the wild-type virus or otherwise survive a virus infection, some of the target strain microorganisms will grow in the presence of the wild-type virus. Such microorganisms are referred to as wild-type virus-resistant microorganisms, and will grow on the agar as “colonies.” Thus, wild-type virus-resistant microorganisms may be isolated in the form of colonies by culturing target strain microorganisms in the presence of a wild-type virus that will infect, or is specific for, the target strain.
  • H-mutant viruses may then be generated and isolated by transferring a sample of the wild-type virus-resistant microorganism from a “colony” on agar, to a liquid or semi-solid growth medium that includes a high concentration of wild-type viruses.
  • the MOI is preferably greater than one.
  • the concentration of wild-type virus-resistant microorganisms will preferably facilitate growth of a confluent layer, which is also typically referred to as a “lawn,” in a semi-solid growth medium.
  • many of the viruses will have no effect on wild-type virus-resistant microorganisms, some mutants will infect and lyse the virus resistant microorganisms. These viruses are the h-mutants, and are isolated within substantially transparent areas of the lawn, which are typically referred to as “plaques.”
  • the processes of isolating virus-resistant target strain microorganisms and generating, selecting, and isolating h-mutant viruses may be repeated in order to increase the range of virus-resistant microorganisms of a target strain that the h-mutant viruses will infect.
  • Such a process may be performed by growing virus-resistant microorganisms in the presence of h-mutant viruses rather than wild-type viruses.
  • various h-mutants with different host ranges may be generated and isolated by conducting these processes several different times.
  • the presence or absence of undesirable genes may be determined by comparison techniques that are known to those in the art, such as conventional agarose gel electrophoresis, pulsed-field gel electrophoresis, or use of nucleic acid hybridization probes.
  • Such techniques include hybridization of any undesirable genes with complementary polymerase chain reaction (PCR)-amplified strands of DNA which include known undesirable genes (e.g., genes that impart the virus with the ability to infect multicellular organisms, the ability to transfer undesirable genes to infected host microorganisms, and the ability to convert from a lytic state to a temperate state).
  • PCR complementary polymerase chain reaction
  • Hybrids may then be detected by known techniques, such as radio-assays.
  • temperate viruses will be screened by comparing the genes of these viruses to known genes that impart viruses with temperate characteristics. Temperate h-mutant viruses may then be excluded from virus mixtures of the present invention and from use in treatment methods of the present invention.
  • Temperate wild-type viruses may be screened and excluded in similar fashion from viruses and virus mixtures of the present invention. As previously identified, temperate viruses may transfer undesirable characteristics to a host target strain of a microorganism. Moreover, temperate viruses do not readily destroy the target strain microorganism. Thus, the use of temperate viruses in controlling, reducing or eliminating microorganism populations is not as desirable as the use of lytic viruses for these purposes.
  • virus-resistant microorganisms that are generated in the foregoing process may be screened for other undesirable characteristics, such as antibiotic resistance, in a similar fashion.
  • viruses of the present invention which lack undesirable characteristics may then be proliferated and utilized in virus mixtures of the present invention, and in accordance with methods of the present invention.
  • a process for proliferating the viruses of the present invention includes growing large quantities of the target strain microorganisms, including one or more virus-resistant variations thereof.
  • the desired virus or viruses such as one or more h-mutant variations or one or more wild-type variations of each desired virus, are then introduced into the presence of the target strain of microorganism at a desired MOI.
  • An exemplary growth chamber comprises a bioreactor, into which nutrients may be continually introduced and from which microorganisms and/or viruses may be continually removed.
  • the virus or viruses may also be proliferated in sterilized liquid growth medium in large flasks, or otherwise as known in the art.
  • the viruses or virus mixtures may be concentrated by methods that are known in the art, such as chemical precipitation and ultrafiltration.
  • Another method of concentrating h-mutant viruses includes isolating and concentrating infected, non-lysed target strain host microorganisms, which are referred to as “carriers.”
  • carriers are desirable because a single carrier will eventually be lysed by viruses growing therein, and during lysis release a large number of viruses.
  • carrier microorganisms by conventional methods, such as centrifugation, than it is to concentrate viruses by many conventional methods.
  • carriers are avirulent variations of the target strain microorganism, so that little or no risk exists of introducing a virulent target strain into a virus treatment site.
  • viruses and carrier microorganisms of viruses may be stored as known in the art (e.g., by refrigeration at about 4° C., freezing or lyophilization processes) prior to use in the process of the invention.
  • the viruses and carriers including the viruses of the present invention may be employed in accordance with a process of the present invention and/or concentration thereof.
  • the virus-resistant microorganisms of the present invention may be concentrated and/or stored in a manner, that is similar to the processes for concentrating and storing the viruses.
  • Stored or unstored viruses and virus mixtures, and virus-resistant microorganisms may then be utilized in accordance with the microorganism population control processes of the present invention, examples of which are set forth in detail below.
  • a first embodiment of the inventive method includes employing viruses or virus mixtures of the present invention to control populations of target strain microorganisms.
  • This first embodiment includes introducing the inventive viruses into a treatment site in order to lyse target strain microorganisms.
  • Foods or food products, such as raw meat and poultry are exemplary treatment sites.
  • the undesirable microorganisms that are typically present in raw meat and poultry treatment sites include, without limitation, the genera Salmonella, Campylobacter , and Escherichia (e.g., E. coli .)
  • An exemplary target strain of E. coli is the infamous strain designated O157:H7.
  • Introducing viruses that will infect and lyse undesirable microorganisms into raw meat and poultry treatment sites includes, but is not limited to, introducing the viruses into food and water of live animals, applying viruses to the living spaces of such animals, applying and otherwise introducing viruses to animal carcasses, meat, and surfaces in meat packing plants, storage and transportation containers, markets, and homes.
  • viruses may be employed in the prevention (i.e., prophylaxis) or treatment (i.e., therapy) of diseases that are caused by a target strain of microorganism.
  • Treatment and prophylaxis both include introducing the viruses into the subject by a known method.
  • the viruses are preferably orally administered by a known enteral dosage form.
  • the viruses may be topically administered in various known forms, such as aerosols, liquids, creams, lotions, soaps, powders, and salves.
  • the viruses of the present invention may also be administered in accordance with processes that are known in the art, such as those disclosed in WO95/27043, the disclosure of which is hereby incorporated by reference in its entirety.
  • viruses of the present invention may be introduced alone or in combination with one or more antibiotics, which are also referred to herein as “antimicrobial agents” or “bacteriocins.”
  • antibiotics which are also referred to herein as “antimicrobial agents” or “bacteriocins.”
  • Bacteriocin was coined for antibacterial agents that are synthesized by bacteria and require specific receptors on the target microorganism.
  • antibiotics and other antimicrobial agents are known in the art (see, e.g., Handbook of Antimicrobial Therapy, The Medical Letter (1984), the disclosure of which is hereby incorporated by reference in its entirety).
  • the viruses of the present invention are especially useful for preventing infection by and treating antibiotic-resistant strains of bacteria.
  • the inventive viruses may also be employed to disinfect a target strain of a microorganism from an object.
  • a composition including the viruses is applied to the object and the viruses lytically infect the target strain.
  • Exemplary objects which may be disinfected in this manner include, but are not limited to, infected areas of healthcare facilities, operating rooms and treatment rooms in healthcare facilities, and equipment that is used by healthcare professionals.
  • Plant diseases that are caused by microorganisms may also be treated in accordance with this first embodiment of the method.
  • the viruses that will infect target strains of plant disease-causing or harmful, e.g., ice-nucleation, microorganisms may be applied to infected or contaminated plants, seedlings, seeds, or soil or other matter which supports the foregoing by spraying or introduction into the plant's water supply.
  • legume seed may be treated with a virus or virus mixture that will infect and lyse undesirable strains of rhizobia that are present in soil, and that will not infect beneficial strains of rhizobia.
  • the virus which preferably includes an h-mutant virus, will reduce or eliminate undesirable rhizobia strains, while the desirable rhizobia strains will benefit the plant as the plant grows.
  • the first embodiment of the method of the present invention may also be employed to control microorganism populations that are detrimental to the environment.
  • the inventive viruses may be employed to reduce populations of microorganisms which deplete oxygen from bodies of water, and permit an increase of oxygen levels in these waters.
  • Nutrients from sewage and fertilizer that are introduced into pond water, river water, or sea water can create algal blooms.
  • the algae eventually die and are then decomposed by various microorganisms, which proliferate and continue decomposing the dead algae.
  • oxygen is depleted from the water, which inhibits growth of most other organisms therein.
  • viruses of the present invention may be employed to reduce the occurrence of “acid mine drainage,” which is an environmental problem associated with coal mining.
  • Thiobacillus ferrooxidans a bacterial species that oxidizes iron sulfide, is a major cause of acid mine drainage.
  • acidic mine drainage pollutes the water in nearby lakes, rivers and streams, the quality of these waters deteriorates.
  • Acid and metals that are dissolved in acid mine drainages are toxic to aquatic life and render the water unsafe for consumption and human activity.
  • the introduction of viruses that will infect and lyse T. ferrooxidans would therefore be useful in reducing or eliminating this type of bacteria from coal mines, and reduce the occurrence of acid mine drainage.
  • pathogenic agents include, but are not limited to, various types of bacterial (e.g., Bacillus anthracis, Salmonella typhi, Vibrio cholerae, Yersina pestis, Xanthomonas albilineans, A. campestris pv. citri , and X. campestris pv. oryzae ) rickettsial (e.g., Coxiella burnetii and Rickettsia prowazeki ), and fungal organisms.
  • inventive viruses that infect and lyse such pathogenic agents into treatment sites where such pathogenic agents are present would control, reduce, and potentially eliminate populations of such pathogenic agents.
  • the first embodiment of the process of the present invention may also be employed to selectively control, reduce or eliminate populations of undesirable microorganisms that inhibit the ability of beneficial microorganisms to perform beneficial processes.
  • beneficial microorganisms or beneficial agents benefit their hosts.
  • the ability of a beneficial microorganism to benefit its host may, however, be interfered with by an undesirable microorganism.
  • a preferred virus or virus mixture that would be useful in treating a target strain of undesirable microorganisms in accordance with the first embodiment of the process would infect and lyse the target strain, and would not infect or lyse any of the beneficial microorganisms.
  • the bioremediation of toxic chemicals by beneficial microorganisms may be interfered with by undesirable target strains of microorganisms.
  • pseudomonads which produce a variety of antimicrobial substances, may be present in a mixture of bioremediating microorganisms.
  • the presence of antimicrobial substances in such mixtures is undesirable since it may destroy the ability of many of the microorganisms to bioremediate toxic chemicals.
  • the viruses of the present invention would be useful in the present method for controlling the number of undesirable antimicrobial-producing microorganisms in such a mixture.
  • P. aeruginosa occurs naturally in soil, and is useful in the bioremediation of many environmental pollutants. P. aeruginosa , however, also causes various diseases in plants and animals. Thus, this method of the invention would be useful for controlling, reducing, or eliminating the population of P. aeruginosa after that microorganism has performed its beneficial task.
  • populations of genetically engineered microorganisms may be controlled, reduced, or eliminated in a similar manner. Since many people fear that the use of genetically engineered microorganisms for beneficial purposes may also have adverse effects, the elimination of such genetically engineered microorganisms may be desirable. Thus, viruses that infect and lyse a target strain of genetically engineered microorganism may be utilized in accordance with this embodiment of the invention to control, reduce, or eliminate populations of genetically engineered target strain microorganisms from a treatment site following their use for beneficial purposes.
  • a second embodiment of the method of the present invention includes the use of virus-resistant strains of beneficial microorganisms in beneficial processes.
  • Virus-resistant microorganisms are generated, as previous described, by growing a target strain of microorganism in the presence of wild-type and/or h-mutant viruses that will infect and lyse the target strain microorganism. Virus-resistant microorganisms may then be isolated as discussed previously, and proliferated in a growth medium under otherwise substantially sterile and preferably controlled conditions.
  • virus-resistant Pantoea ananus which is parasitic for the rust fungi, Puccinia spp.
  • Phages which attack P. ananus are, however, also present in proximity to the rust fungus, and have a detrimental effect on the ability of P. ananus to control rust fungus.
  • the application of virus-resistant strains of P. ananus to wheat would be useful in controlling the growth of rust fungus on the wheat.
  • the application of virus-resistant P. ananus to rust fungus-infected wheat would be useful for preventing the spread of rust fungus to other wheat plants, and for treating the rust fungus-infected wheat plants.
  • bacteria such as Serratia entomophilia
  • control the proliferation and spread of insect populations such as New Zealand grass grub, or Costelytra zealandica
  • insect populations such as New Zealand grass grub, or Costelytra zealandica
  • Other virus-resistant bacteria used for biological pest control such as Enterobacter aerogenes for locusts, are also useful in the second embodiment of the process of the present invention.
  • beneficial microorganisms are useful for performing processes which include, without limitation, leaching in order to oxidize the sulfide of sulfide-rich minerals to sulfuric acid so as to liberate and concentrate valuable minerals, such as copper and uranium, from low-grade ores (i.e., T.
  • ferrooxidans and Acidiphilium spp. releasing petroleum and related substances from bituminous shale (e.g., Rhodococcus spp., Sulfobus spp., and/or Thiobacillus spp.); acidifying sulfur or other matter to acidify alkaline soils that have been selected for agricultural uses (e.g., Rhodococcus spp., Sulfobus spp., and/or Thiobacillus spp.); decomposing tires and other rubber products for recycling (e.g., Rhodococcus spp., Sulfobus spp., and/or Thiobacillus spp.); bioremediation of hazardous chemicals and pollutants (e.g., Rhodococcus spp., Sulfobus spp., and/or Thiobacillus spp.); treatment of wastewater discharges and sludges in which other microorganisms produce foul-smelling odors (e.g.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cash Registers Or Receiving Machines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
US11/033,022 2005-01-10 2005-01-10 Use of viruses and virus-resistant microorganisms for controlling microorganism populations Abandoned US20060153811A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US11/033,022 US20060153811A1 (en) 2005-01-10 2005-01-10 Use of viruses and virus-resistant microorganisms for controlling microorganism populations
JP2007550568A JP2008526892A (ja) 2005-01-10 2006-01-10 食品の処理方法
PCT/US2006/000854 WO2006074460A2 (en) 2005-01-10 2006-01-10 Method of treating food products
CA2593680A CA2593680C (en) 2005-01-10 2006-01-10 Methods of generating host range mutant viruses and virus-resistant microorganisms
KR1020077018327A KR20070118072A (ko) 2005-01-10 2006-01-10 식료품 처리 방법
CNA2006800044501A CN101115393A (zh) 2005-01-10 2006-01-10 处理食品的方法
MX2007008391A MX349342B (es) 2005-01-10 2006-01-10 Método para tratar productos alimenticios.
AU2006203859A AU2006203859A1 (en) 2005-01-10 2006-01-10 Method of treating food products
EP06717987.9A EP1845784B1 (en) 2005-01-10 2006-01-10 Method of treating food products
US11/831,813 US20070292395A1 (en) 2005-01-10 2007-07-31 Use of viruses and virus-resistant microorganisms for controlling microorganism populations
US12/027,209 US8821855B2 (en) 2005-01-10 2008-02-06 Methods for isolating phage and for controlling microorganism populations with the phage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/033,022 US20060153811A1 (en) 2005-01-10 2005-01-10 Use of viruses and virus-resistant microorganisms for controlling microorganism populations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/831,813 Division US20070292395A1 (en) 2005-01-10 2007-07-31 Use of viruses and virus-resistant microorganisms for controlling microorganism populations
US12/027,209 Division US8821855B2 (en) 2005-01-10 2008-02-06 Methods for isolating phage and for controlling microorganism populations with the phage

Publications (1)

Publication Number Publication Date
US20060153811A1 true US20060153811A1 (en) 2006-07-13

Family

ID=36648261

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/033,022 Abandoned US20060153811A1 (en) 2005-01-10 2005-01-10 Use of viruses and virus-resistant microorganisms for controlling microorganism populations
US11/831,813 Abandoned US20070292395A1 (en) 2005-01-10 2007-07-31 Use of viruses and virus-resistant microorganisms for controlling microorganism populations
US12/027,209 Active US8821855B2 (en) 2005-01-10 2008-02-06 Methods for isolating phage and for controlling microorganism populations with the phage

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/831,813 Abandoned US20070292395A1 (en) 2005-01-10 2007-07-31 Use of viruses and virus-resistant microorganisms for controlling microorganism populations
US12/027,209 Active US8821855B2 (en) 2005-01-10 2008-02-06 Methods for isolating phage and for controlling microorganism populations with the phage

Country Status (9)

Country Link
US (3) US20060153811A1 (ja)
EP (1) EP1845784B1 (ja)
JP (1) JP2008526892A (ja)
KR (1) KR20070118072A (ja)
CN (1) CN101115393A (ja)
AU (1) AU2006203859A1 (ja)
CA (1) CA2593680C (ja)
MX (1) MX349342B (ja)
WO (1) WO2006074460A2 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127795A2 (en) 2007-02-28 2008-10-23 Omnilytics, Inc. External animal layer sanitation using bacteriophage
US20100068337A1 (en) * 2008-09-17 2010-03-18 Reber Justin C Packaged animal foods including beneficial viruses, methods for packaging and storing animal foods, and methods for feeding animals
US20100068777A1 (en) * 2008-09-17 2010-03-18 Omnilytics, Incorporated Methods for producing biofuels and compositions for use in biofuel production methods
US20100068338A1 (en) * 2008-09-17 2010-03-18 Reber Justin C Animal foods including beneficial viruses, methods for packaging and storage of animal foods, and methods for feeding animals
US20100068185A1 (en) * 2008-09-17 2010-03-18 Omnilytics, Incorporated Methods for introducing bacteriophage into the interiors of quantities of edible agricultural products and edible agricultural products with phage-containing preparations in the interiors thereof
WO2011003075A1 (en) * 2009-07-02 2011-01-06 Allegheny-Singer Research Institute Biofilm remediation of acid mine drainage

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2126130B1 (en) * 2007-03-02 2015-03-25 DuPont Nutrition Biosciences ApS Cultures with improved phage resistance
EP2197284B1 (en) * 2007-10-04 2017-04-12 AmpliPhi Biosciences Corporation Anti-bacterial compositions
US10626375B2 (en) 2014-06-25 2020-04-21 Auxergen, Inc. Disease control of the plant bacterial pathogens causing citrus canker and rice blight

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375734A (en) * 1981-08-17 1983-03-08 University Patents, Inc. Protection of plants against frost injury using ice nucleation-inhibiting species-specific bacteriophages
US4828999A (en) * 1986-07-21 1989-05-09 Jackson Le Roy E Bacteriophage prevention and control of harmful plant bacteria
US5447836A (en) * 1988-10-04 1995-09-05 Dna Plant Technology Corporation Bacterial detection by phage transduction of ice nucleation and other phenotypes
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
US7521201B2 (en) * 2004-11-01 2009-04-21 Strategic Diagnostics Inc. Bacteriophages as selective agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129343A3 (en) * 1983-05-19 1987-11-04 Richard Glover Markham Ascorbic acid derivatives and a method for their preparation
SE8505027D0 (sv) 1985-10-24 1985-10-24 Kabigen Ab A lytic virulent phage, a hostcell containing same and a process for protein production
US5132221A (en) * 1989-05-10 1992-07-21 The United States Of America As Represented By The United States Department Of Energy Lysogenic bacteriophage isolated from acidophilium
US5366891A (en) * 1992-03-18 1994-11-22 Associated Universities, Inc. Biochemical solubilization of toxic salts from residual geothermal brines and waste waters
WO1995027043A1 (en) * 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
IES70514B2 (en) * 1995-04-12 1996-12-11 Teagasc Agric Food Dev Authori Bacteriocins
EP0895534A1 (en) * 1996-04-15 1999-02-10 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
JP2002335957A (ja) * 1996-08-26 2002-11-26 Bio Venture Bank Kk 新規なバクテリオファージならびにそのスクリーニング法 およびそれを使用した新規バイオ殺菌材料ならびに検出用 試薬
AU3869297A (en) 1996-08-26 1998-03-19 Bio Benture Bank Co., Ltd. Novel bacteriophage, method for screening the same, novel biobactericidal materials prepared with the use of the same, and reagent for detecting the same
AU2001230889A1 (en) * 2000-01-11 2001-07-24 Intralytix, Inc. Method and device for sanitation using bacteriophages
CA2479897A1 (en) * 2002-03-25 2003-10-02 David Allan Hodgson Bacteriophages useful for therapy and prophylaxis of bacterial infections

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375734A (en) * 1981-08-17 1983-03-08 University Patents, Inc. Protection of plants against frost injury using ice nucleation-inhibiting species-specific bacteriophages
US4828999A (en) * 1986-07-21 1989-05-09 Jackson Le Roy E Bacteriophage prevention and control of harmful plant bacteria
US5447836A (en) * 1988-10-04 1995-09-05 Dna Plant Technology Corporation Bacterial detection by phage transduction of ice nucleation and other phenotypes
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
US7521201B2 (en) * 2004-11-01 2009-04-21 Strategic Diagnostics Inc. Bacteriophages as selective agents

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127795A2 (en) 2007-02-28 2008-10-23 Omnilytics, Inc. External animal layer sanitation using bacteriophage
US20100068337A1 (en) * 2008-09-17 2010-03-18 Reber Justin C Packaged animal foods including beneficial viruses, methods for packaging and storing animal foods, and methods for feeding animals
US20100068777A1 (en) * 2008-09-17 2010-03-18 Omnilytics, Incorporated Methods for producing biofuels and compositions for use in biofuel production methods
US20100068338A1 (en) * 2008-09-17 2010-03-18 Reber Justin C Animal foods including beneficial viruses, methods for packaging and storage of animal foods, and methods for feeding animals
US20100068185A1 (en) * 2008-09-17 2010-03-18 Omnilytics, Incorporated Methods for introducing bacteriophage into the interiors of quantities of edible agricultural products and edible agricultural products with phage-containing preparations in the interiors thereof
WO2010033737A3 (en) * 2008-09-17 2010-07-22 Omnilytics, Incorporated Methods for producing biofuels and compositions for use in biofuel production methods
WO2011003075A1 (en) * 2009-07-02 2011-01-06 Allegheny-Singer Research Institute Biofilm remediation of acid mine drainage
US20110100906A1 (en) * 2009-07-02 2011-05-05 Allegheny-Singer Research Institute Biofilm remediation of acid mine drainage
US8480902B2 (en) 2009-07-02 2013-07-09 Allegheny-Singer Research Institute Biofilm remediation of acid mine drainage

Also Published As

Publication number Publication date
US20070292395A1 (en) 2007-12-20
CA2593680A1 (en) 2006-07-13
CA2593680C (en) 2016-10-11
MX349342B (es) 2017-07-25
EP1845784A2 (en) 2007-10-24
WO2006074460A2 (en) 2006-07-13
KR20070118072A (ko) 2007-12-13
CN101115393A (zh) 2008-01-30
MX2007008391A (es) 2007-11-21
AU2006203859A1 (en) 2006-07-13
US8821855B2 (en) 2014-09-02
WO2006074460A3 (en) 2006-12-07
EP1845784B1 (en) 2020-11-18
EP1845784A4 (en) 2012-10-17
JP2008526892A (ja) 2008-07-24
US20080124305A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
US8821855B2 (en) Methods for isolating phage and for controlling microorganism populations with the phage
Wang et al. Characterization of a broad host-spectrum virulent Salmonella bacteriophage fmb-p1 and its application on duck meat
Viazis et al. Reduction of Escherichia coli O157: H7 viability on hard surfaces by treatment with a bacteriophage mixture
Goodridge et al. Bacteriophage biocontrol and bioprocessing: application of phage therapy to industry
Soni et al. Bacteriophage significantly reduces Listeria monocytogenes on raw salmon fillet tissue
Sasikala et al. Characterization of potential lytic bacteriophage against Vibrio alginolyticus and its therapeutic implications on biofilm dispersal
Gong et al. Application of bacteriophages to reduce Salmonella attachment and biofilms on hard surfaces
Heyse et al. Bacteriophage cocktail for biocontrol of Salmonella in dried pet food
Lee et al. Characteristics of coliphage ECP4 and potential use as a sanitizing agent for biocontrol of Escherichia coli O157: H7
Oh et al. Isolation and characterization of Bacillus cereus bacteriophages from foods and soil
Kenney et al. Persistence of Escherichia coli O157: H7, Salmonella Newport, and Salmonella Poona in the gut of a free-living nematode, Caenorhabditis elegans, and transmission to progeny and uninfected nematodes
Shahin et al. Effective control of Shigella contamination in different foods using a novel six-phage cocktail
Karunasagar et al. Biocontrol of bacterial pathogens in aquaculture with emphasis on phage therapy
Ahmed et al. Bacteriophage therapy revisited
Ottaviani et al. Vibrio parahaemolyticus control in mussels by a Halobacteriovorax isolated from the Adriatic sea, Italy.
Smirnov et al. Perspectives of the use of bacteriophages in agriculture, food and processing industries
Ahmad et al. Biocontrol effect of lytic bacteriophages against various foodborne diseases
Jung et al. Isolation and characterization of multidrug-resistant Salmonella-specific bacteriophages and their antibacterial efficiency in chicken breast
Yan et al. Biological characterization of Pseudomonas fluorescens phage Pf17397_F_PD1 and its application in food preservation
Brenner et al. Reduction of nontyphoidal Salmonella enterica in broth and on raw chicken breast by a broad-spectrum bacteriophage cocktail
Zaiko et al. Antibiotic resistant of microorganisms in fermented sausages
Brauer et al. Biocontrol for foodborne zoonotic pathogens in animal reservoirs and food products
Ameh The use of bacteriophages as natural biocontrol agents against bacterial pathogens
Akindolire Molecular characterisation of Escherichia coli O157: H7 specific bacteriophages from cattle faeces
Selvaraj et al. The Predatory Bacteria, Bdellovibrio and Like Organisms (BALOs): An Emerging Savior for Human Welfare

Legal Events

Date Code Title Description
AS Assignment

Owner name: OMILYTICS, INCORPORATED, UTAH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JACKSON, LEE E.;SPENDLOVE, REX S.;REEL/FRAME:016507/0645;SIGNING DATES FROM 20041201 TO 20041220

AS Assignment

Owner name: OMNILYTICS, INCORPORATED, UTAH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SPENDLOVE, REX S.;JACKSON, LEE E.;REEL/FRAME:021458/0846;SIGNING DATES FROM 20041201 TO 20041220

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION